707 related articles for article (PubMed ID: 16115812)
1. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
[TBL] [Abstract][Full Text] [Related]
2. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism.
Lee JM; Ivanova EV; Seong IS; Cashorali T; Kohane I; Gusella JF; MacDonald ME
PLoS Genet; 2007 Aug; 3(8):e135. PubMed ID: 17708681
[TBL] [Abstract][Full Text] [Related]
3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
4. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
5. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
Wang H; Lim PJ; Karbowski M; Monteiro MJ
Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice.
Oliveira JM; Jekabsons MB; Chen S; Lin A; Rego AC; Gonçalves J; Ellerby LM; Nicholls DG
J Neurochem; 2007 Apr; 101(1):241-9. PubMed ID: 17394466
[TBL] [Abstract][Full Text] [Related]
7. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS
Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599
[TBL] [Abstract][Full Text] [Related]
8. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
[TBL] [Abstract][Full Text] [Related]
9. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
10. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
Oliveira JM
J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
[TBL] [Abstract][Full Text] [Related]
11. Deranged neuronal calcium signaling and Huntington disease.
Bezprozvanny I; Hayden MR
Biochem Biophys Res Commun; 2004 Oct; 322(4):1310-7. PubMed ID: 15336977
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat.
Matsuyama N; Hadano S; Onoe K; Osuga H; Showguchi-Miyata J; Gondo Y; Ikeda JE
Genomics; 2000 Oct; 69(1):72-85. PubMed ID: 11013077
[TBL] [Abstract][Full Text] [Related]
13. Metabolism in HD: still a relevant mechanism?
Duan W; Jiang M; Jin J
Mov Disord; 2014 Sep; 29(11):1366-74. PubMed ID: 25124273
[TBL] [Abstract][Full Text] [Related]
14. HD CAG-correlated gene expression changes support a simple dominant gain of function.
Jacobsen JC; Gregory GC; Woda JM; Thompson MN; Coser KR; Murthy V; Kohane IS; Gusella JF; Seong IS; MacDonald ME; Shioda T; Lee JM
Hum Mol Genet; 2011 Jul; 20(14):2846-60. PubMed ID: 21536587
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.
Fernandes HB; Baimbridge KG; Church J; Hayden MR; Raymond LA
J Neurosci; 2007 Dec; 27(50):13614-23. PubMed ID: 18077673
[TBL] [Abstract][Full Text] [Related]
16. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.
Choo YS; Johnson GV; MacDonald M; Detloff PJ; Lesort M
Hum Mol Genet; 2004 Jul; 13(14):1407-20. PubMed ID: 15163634
[TBL] [Abstract][Full Text] [Related]
17. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
[TBL] [Abstract][Full Text] [Related]
18. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
19. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
[TBL] [Abstract][Full Text] [Related]
20. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
